Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in association with a third-generation antifolate is the front-line standard of care whereas any second-line treatment was approved for MPM thus making it a pathology that evokes the need for new therapeutic agents. Different platinum-drugs were synthesised and tested as an option for patients who are not candidates to cisplatin-based therapy. Among these, monofunctional cationic antineoplastic platinum compounds received a special attention in the last decade. Alternative strategies to the commonly used combination-therapy resulted from the use of Mesenchymal Stromal Cells (MSC) widely used in the field of regenerative medicine and recently proposed as natural carriers for a selective delivery of chemotherapeutic agents and from the use of immune checkpoint and kinase inhibitors. The present short review shed light on the recent state of art and the future perspectives relative to MPM therapy.

Malignant Pleural Mesothelioma : State of the art and advanced cell therapy / G. Facchetti, F. Petrella, L. Spaggiari, I. Rimoldi. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 142(2017 Dec), pp. 266-270. [10.1016/j.ejmech.2017.07.063]

Malignant Pleural Mesothelioma : State of the art and advanced cell therapy

G. Facchetti;F. Petrella
Secondo
;
L. Spaggiari
Penultimo
;
I. Rimoldi
Ultimo
2017-12

Abstract

Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in association with a third-generation antifolate is the front-line standard of care whereas any second-line treatment was approved for MPM thus making it a pathology that evokes the need for new therapeutic agents. Different platinum-drugs were synthesised and tested as an option for patients who are not candidates to cisplatin-based therapy. Among these, monofunctional cationic antineoplastic platinum compounds received a special attention in the last decade. Alternative strategies to the commonly used combination-therapy resulted from the use of Mesenchymal Stromal Cells (MSC) widely used in the field of regenerative medicine and recently proposed as natural carriers for a selective delivery of chemotherapeutic agents and from the use of immune checkpoint and kinase inhibitors. The present short review shed light on the recent state of art and the future perspectives relative to MPM therapy.
Malignant pleural mesothelioma (MPM); Cisplatin derivatives; Cationic platinum complex; Pemetrexed; Mesenchymal stromal cells (MSC)
Settore MED/21 - Chirurgia Toracica
Settore CHIM/03 - Chimica Generale e Inorganica
Article (author)
File in questo prodotto:
File Dimensione Formato  
MalignantPleuralMesothelioma_SpaggiariEtAlii.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 361.91 kB
Formato Adobe PDF
361.91 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Review Rimoldi&co._revised.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 303.76 kB
Formato Adobe PDF
303.76 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/521166
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact